Evidence map›Paper›PMID 28927120›Full record

ArticleOncology letters2017

Expression and clinical significance of SATB1 and TLR4 in breast cancer.

Xuebo Wang, Xiumei Yu, Qingli Wang, Yingying Lu, Haixia Chen

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. The Role of SATB1 in Tumour Progression and Metastasis.International journal of molecular sciences · 2019
    Review
  13. TLR4 Polymorphisms and Expression in Solid Cancers.Molecular diagnosis & therapy · 2018
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Xuebo WangDepartment of Clinical Laboratory, Yuhuangding Hospital of Yantai, Yantai, Shandong 264000, P.R. China.
Xiumei YuDepartment of Clinical Laboratory, Yuhuangding Hospital of Yantai, Yantai, Shandong 264000, P.R. China.
Qingli WangDepartment of Cardiology, The People's Hospital of Zhangqiu, Zhangqiu, Shandong 250200, P.R. China.
Yingying LuDepartment of Clinical Laboratory, People's Hospital of Rizhao, Rizhao, Shandong 276800, P.R. China.
Haixia ChenDepartment of Clinical Laboratory, Yeda Hospital of Yantai, Yantai, Shandong 264000, P.R. China.
Yuhuangding Hospital · CNPeople’s Hospital of Rizhao · CNYantaishan Hospital · CNZhangqiu City People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigated the expression of special AT-rich sequence-binding protein 1 (SATB1) and toll-like receptor 4 (TLR4) protein in breast cancer and its clinical significance. We collected breast cancer tissues from 120 patients and adjacent non-cancerous tissue from 53 patients. SATB1 was expressed in 89 cases of breast cancer (74.17%) and in 7 cases of adjacent non-cancerous tissue (13.21%). TLR4 was expressed in 70 cases of breast cancer tissues (58.33%) and in 48 cases of adjacent non-cancerous tissue (90.57%). The differences of SATB and TLR4 in breast cancer and adjacent non-cancerous tissue were statistically significant. We found a negative correlation between the expression of SATB1 and TLR4 (r=-0.624, P<0.05). The expression of SATB1 and TLR4 were not significantly correlated with age, menopause, and PR and HER-2 protein expression, but were significantly correlated with tumor size, local lymphatic metastasis, histopathological grade, tumor stage, and ER protein expression (P<0.05). Overall, SATB1 and TLR4 proteins are involved in the development of breast cancer, a finding of great significance to identify therapeutic targets and prognosis markers for breast cancer.

Indexed as

breast cancerspecial AT-rich sequence-binding protein 1toll-like receptor 4

Identifiers

PMID28927120
PMCPMC5587979
OpenAlexW2736185144

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.